Buscar

The study could expand to a quarter million people, making Nevada the only state in the U.S. to offer such a program. Las Vegas, Nev. (2 de mayo de 2019) – El Healthy Nevada Project, un estudio de salud poblacional basado en la comunidad primero en su clase que combina datos genéticos, clínicos, ambientales y sociales, está ampliando la inscripción a Las Vegas. The Project aspires not only to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile but ultimately, to develop and expand the Project for communities across the United States to drive positive health outcomes nationwide.   Se agregarán 25,000 voluntarios del estudio en el sur de Nevada El Healthy Nevada Project anuncia extensión a nivel estatal: abre 25,000 vacantes para pruebas en Las Vegas. Ahora que el sur de Nevada abre sus puertas al estudio, el Healthy Nevada Project ofrecerá pruebas genéticas sin costo mediante una muestra de saliva simple a 25,000 voluntarios del estudio. Study volunteers will take Helix’s clinical-grade DNA saliva test and will receive their ancestry and traits, at no cost, through the My Healthy Nevada Traits app. Participants will then be given a chance to answer a follow-up health survey from Renown Institute for Health Innovation (Renown IHI), and upon survey completion, will be entered to win an iPhone. In addition, study participants can agree to be notified about genetic test results that could impact their health, and which could be used to improve their medical care. This return of clinical results, plus genetic counseling and other genetic services as appropriate, will be provided by Genome Medical, the leading network of clinical genetics specialists.   Evolución y expansión continua del Healthy Nevada Project Con más de 35,000 participantes del estudio inscritos en apenas más de dos años, el Healthy Nevada Project se ha convertido en el estudio genético de más rápida inscripción del país. The Project was created by Renown IHI – a collaboration between Reno, Nev.-based not-for-profit health network, Renown Health, and the world leader in environmental data, Desert Research Institute (DRI). Leveraging Renown’s forward-thinking approach to community health care and DRI’s data analytics and environmental expertise, Renown IHI has grown its capabilities to lead a larger, more complex research study of significance that will analyze and model public health risks in Nevada and serve as a national model for future population health studies working to improve overall health through clinical care integration. En el lanzamiento piloto del proyecto el 2016 de septiembre, se inscribieron más de 10,000 miembros de la comunidad para realizarse pruebas de ADN en solo 48 horas. En marzo de 2018, en la fase dos, se les ofreció a los residentes del norte de Nevada secuenciación genómica completa mediante una simple prueba de saliva de Helix. En octubre de 2018, el proyecto anunció la devolución de los resultados clínicos a los participantes del estudio. Allí se notificaba el riesgo que tenían de padecer afecciones de Nivel 1 de los CDC, que incluyen hipercolesterolemia familiar, BRCA1 y BRCA2 positivo, y síndrome de Lynch, un precursor del cáncer de colon. These conditions affect more than one percent of the population and are inherited so they impact family members as well. Ahora, el proyecto anunció su próxima fase: la extensión de la inscripción a 25,000 personas del sur de Nevada.   Serving as a National Model This expansion to Las Vegas truly makes this the “Healthy Nevada Project” with a statewide impact making Nevada the only state in the U.S. to offer such a program. “Nevada was ripe to advance population health goals because, sadly, our state ranks near the bottom in health outcomes. The Healthy Nevada Project is working to change that,” said Anthony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health and president of Renown IHI. “Nuestros investigadores están trabajando en una serie de programas clínicos y estudios científicos para determinar por qué en el condado de Washoe, el condado en el que se encuentra Renown Health, las tasas de mortalidad etarias para enfermedad cardíaca, cáncer y enfermedad crónica de las vías respiratorias inferiores de Nevada son un 33 por ciento más altas que la tasa nacional. Imagine if we can gather more data like this on a national scale and use it to change the future of health and health care? That is what the Healthy USA Project is looking to do in the years to come.” “The Healthy Nevada Project is committed to providing study participants clinically actionable data that will help improve their health,” said Joseph Grzymski, Ph.D., associate research professor at DRI, principal investigator of the Healthy Nevada Project and chief scientific officer for Renown Health. “We are providing this information at the individual level so study volunteers can make lifesaving changes to reduce their risk. We’re also doing it on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country.”   Expanding to Become the Healthy USA Project The accelerated speed of the Project is made possible thanks to the ever-decreasing cost of sequencing. Hoy en día, Helix puede secuenciar un exoma completo, lo que permite informar sobre la mayoría de los conocimientos genómicos prácticos, por una fracción de lo que habría costado hace solo 10 años. Additionally, advances in digital health mean Helix and Project researchers can capture unprecedented amounts of health data digitally, making significant contributions to advancing precision health. The partnership has managed to remove the traditional barriers of population health studies, including the difficulty in recruiting participants, establishing quality high through put lab systems, and scaling interpretation and return of results. This development will be key as other health systems around the country join the Project. “We are thrilled to see the constant, fast-paced evolution of this Project with Renown IHI,” said Justin Kao, CoFounder of Helix. “In less than a year, we have sequenced the DNA of thousands of study participants and are now preparing to offer this incredible study in other states. Combining environmental, clinical, social and genetic data allows us to discover risk factors within communities and help people take action to live longer, healthier lives. That’s what makes the next step of the Healthy USA Project so exciting for all of us. “Los detalles completos sobre la evolución del estudio y de la inscripción en el sur de Nevada se darán a conocer en un evento de prensa en Las Vegas el martes 7 de mayo a las 3 p.m. Renown Institute for Health Innovation es una colaboración entre Renown Health, una red de atención médica integrada de administración y propiedad local y sin fines de lucro que brinda servicios a Nevada, Lake Tahoe y el noreste de California, y el Desert Research Institute, líder mundial reconocido en la investigación de los efectos del cambio ambiental natural e inducido por el humano y en la promoción de tecnologías para la evaluación de un planeta cambiante. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Obtenga más información en https://healthynv.org/.  Helix es una empresa de genómica con una misión simple pero potente: to empower every person to improve their life through DNA. Our affordable, turnkey population health solution enables institutions to quickly scale projects that engage communities and accelerate research and discovery, ultimately allowing every person to benefit from the power of genomics. We've also created the first marketplace for DNA-powered products where people can explore diverse and uniquely personalized products developed by high-quality partners, providing powerful tools to increase engagement and speed the pace of population-scale genomics. Helix is headquartered in the San Francisco Bay Area, has an office in Denver, Colorado and operates a CLIA-certified and CAP-accredited next-generation sequencing lab in San Diego powered by Illumina (NASDAQ: ILMN) NGS technology. Helix fue creada en 2015. Obtenga más información en www.helix.com. Helix, el logotipo de Helix y Exome+ son marcas comerciales de Helix Opco, LLC. All other trademarks referenced herein are the property of their respective owners.   Additional Media Contacts: Tracy Bower                                                                                                                                                                          DRI                                                                                                                                                                                      702-862-5404                                                                                                                                                      media@dri.edu Eric Schubert                                                                                                                                                                        Seismic for Helix                                                                                                                                                                    415-939-4366                                                                                                                                                    press@helix.com

Leer más About Estudio de salud poblacional se extiende a todo el estado y abre la inscripción

Physician researchers seek to understand how the immune system responds to COVID-19 and create a healthier Nevada. During the early stages of the pandemic, convalescent plasma was considered the only viable treatment option available for patients with COVID-19. Convalescent plasma is the component of the blood from recovered patients that may contain COVID-19 antibodies that help fight the infection. The National Institutes of Health has since developed treatment guidelines for COVID-19 based on clinical trial data and many studies are still underway worldwide assessing various additional treatment options. Convalescent plasma was in high demand but difficult to locate for COVID-19 patients in the northern Nevada area. A 24-year-old nursing assistant, Austin Meegan, was hospitalized and spent weeks staving off kidney and lung failure before learning he was eligible for an experimental blood transfusion that showed promise in treating COVID-19. Los médicos estimaron que Meegan solo tenía un 3 % de posibilidades de encontrar un donante compatible con su raro tipo de sangre. A COVID-19 survivor, Thomas Gibson, a Texas resident with the same blood type, traveled to Reno to donate his viral antibodies and a convalescent plasma donation credited with helping to save Meegan’s life. Physician clinical researchers and scientists at Renown and the University of Nevada, Reno School of Medicine (UNR Med) knew they needed to create better options for patients and physicians. Clinical researchers developed a study to help other patients like Austin, and pleaded for donations from recovered COVID-19 patients to donate their convalescent plasma. The researcher teams looked to understand how the body’s immune system responds to the virus over time, to aid them in developing new treatments for COVID-19. “The world’s capacity to get through the COVID crisis will depend on four things — science, technology, innovation and partnerships, says Tony Slonim, MD, DrPH, President and CEO of Renown Health.  “Taking lab bench discoveries to the bedside of patients in an efficacious and timely manner is not easy, but with UNR Med and our partners, we are making great strides in advancing clinical research which has the power to save lives and to create a healthier Nevada.” “It’s tremendously promising to partner on clinical research that will not only help us better understand the disease, but help inform treatment for those combatting COVID-19 that has had such a devastating impact on Nevadans, our nation and the world,” says UNR Med Dean Thomas L. Schwenk, MD. Renown, UNR Med and other area health care partners collaborated with Vitalant to collect plasma from recovered donors for a study on the treatment's efficacy. Los donantes elegibles tenían al menos 18 años, pesaban más de 110 libras y estaban sanos. Donors had fully recovered from a confirmed diagnosis of COVID-19. Project coordinators at the Renown Research Office were overwhelmed by the community’s support and plasma blood donations. Las asociaciones adicionales con el Distrito de Salud del Condado de Washoe, el estado de Nevada y la Oficina del Gobernador, Saint Mary’s Medical Center, Northern Nevada Medical Center, Carson Tahoe Health y VA Sierra Nevada Health Care System, junto con muchos proveedores de atención médica del área, ayudaron al equipo a alcanzar sus objetivos de inscribir a 120 participantes elegibles en el estudio. “Our success in this study rests heavily on the support of our great community, as well as the innovation and collaboration demonstrated by Renown and UNR Med,” said Sara Healy, MD, MPH, principal investigator of the study and a pediatric infectious disease physician at Renown Children’s Hospital and UNR Med. “We are proud to be at the forefront of conducting essential research during such a pivotal time in history, and look forward to our continued partnership as we continue this important work.” “The control of COVID-19 in our communities relies on testing. The study that is being launched to develop a sensitive, specific and easier way to collect specimens (blood) is advancing the field and brings promise towards getting to our common goal of having the right diagnostic test for the right clinical situation at the right time,” says Mark Riddle, MD, DrPH, FISTM, associate investigator of the study and associate dean for clinical research and professor at UNR Med's Department of Internal Medicine and Medical Research. The research team is now asking area residents to participate in a study to analyze the efficacy of two COVID-19 tests. Participants will undergo two blood tests: one being a finger stick to provide results for a rapid test, and the other is a traditional venipuncture draw confirming the presence or absence of COVID-19 antibodies. This study is a collaboration with InBios International, Inc., a leading biotechnology company based in Seattle. Researchers are seeking: Individuals who have confirmed positive for COVID-19 and who have recently recovered from the virus. Los participantes del estudio deben estar en un período de entre 7 y 28 días posteriores al inicio de sus síntomas. Individuals who have recently tested negative for COVID-19 and have never tested positive. Los interesados en participar en el estudio pueden ponerse en contacto con los coordinadores del proyecto en la Oficina de Investigación de Renown al (775) 982-3646, o por correo electrónico a covidplasmascreening@renown.org, de lunes a viernes, de 7:30 a.m. a 5:00 p.m. Se anima a las personas de entre 18 y 75 años con buena salud en general a que consideren la posibilidad de participar en este estudio en curso. There is no cost to participate in this study and participation is voluntary. An individual’s decision to participate will not affect their current or future relations with their health care provider(s), health district, or the community. Those who decide to participate are free to withdraw at any time. “Time is of the essence with COVID. If we can get test results to people and their clinicians in a more timely way, we can make a faster diagnosis of a patient's condition, says Christopher M. Kozlowski, MD, MHA, Renown's institutional research officer and Medical Director/VP of Renown Institute for Heart & Vascular Health. “As we refine the accuracy of our testing; we are applying sensitivity and specificity testing for true negative and true positive results. This provides people with more timely and accurate results and better quality care.”     Acerca de Renown Health Renown Health es una red de atención médica integrada de administración local y sin fines de lucro que brinda servicios al norte de Nevada, Lake Tahoe y el noreste de California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown tiene una larga trayectoria y un compromiso de larga data con la mejora de la atención y la salud de nuestra comunidad.     About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Fundada en 1969, la UNR Med está mejorando la salud y el bienestar de todos los residentes de Nevada y sus comunidades mediante excelencia en la educación estudiantil, capacitación de posgrado y atención clínica, investigación con impacto local, nacional y global y una cultura de diversidad e inclusión. For more information, visit med.unr.edu.

Leer más About Researchers at Renown Seek Convalescent Plasma Study Participants